Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma by Carmen Choi, Mathias Witzens, Marianna.

Slides:

Advertisements

Similar presentations

Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma by Maurizio Chiriva-Internati, Zhiqing Wang, Emanuela Salati, Klaus.

Advertisements

Volume 17, Issue 9, Pages (September 2015)

Volume 2, Issue 10, Pages (October 2015)

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and.

by Jane Yui, Choy-Pik Chiu, and Peter M. Lansdorp

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells by Susanne M. Schmidt,

Depletion of Alloreactive Donor T Lymphocytes by CD95-Mediated Activation-Induced Cell Death Retains Antileukemic, Antiviral, and Immunoregulatory T Cell.

Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators by Rikke Bæk Sørensen, Sine Reker Hadrup, Inge Marie Svane, Mads Christian.

by Masih Ostad, Margareta Andersson, Astrid Gruber, and Anne Sundblad

by Rui Zhang, Jeffrey D. Lifson, and Claire Chougnet

Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses by Giulia Nizzoli, Jana Krietsch, Anja Weick, Svenja.

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas by Jinsheng Weng, Seema Rawal, Fuliang Chu, Hyun Jun Park, Rakesh Sharma,

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients by Nicola Giuliani, Francesca Morandi, Sara Tagliaferri, Simona Colla,

Krystel Vincent, Marie-Pierre Hardy, Assya Trofimov, Céline M

Mutagenic potential of temozolomide in bone marrow cells in vivo

ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1–restricted CD8+ T-cell epitopes by Lorena Passoni, Antonio Scardino, Carla.

Impaired function of human T-lymphotropic virus type 1 (HTLV-1)–specific CD8+ T cells in HTLV-1–associated neurologic disease by Amir H. Sabouri, Koichiro.

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion by Yenan T. Bryceson, Michael E. March, Hans-Gustaf.

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells by Ennio Carbone, Paola Neri,

by Norman Nausch, Ioanna E

Novel function for interleukin-7 in dendritic cell development

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer by Jeffrey S. Miller, Yvette Soignier, Angela.

Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants by Georg.

Altered Homeostasis of CD4+ Memory T Cells in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Chronic Graft-versus-Host Disease Enhances T Cell.

Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA by Caterina Milazzo, Volker L. Reichardt, Martin.

Mature dendritic cells pulsed with freeze–thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte.

HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,

Multiple myeloma–reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR)

Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo by Suzanne M. McGoldrick, Marie E. Bleakley,

Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses by Cagan Gurer, Till.

by Vladia Monsurrò, Ena Wang, Yoshisha Yamano, Stephen A

Adoptive Cellular Therapy using Cells Enriched for NKG2D+CD3+CD8+T Cells after Autologous Transplantation for Myeloma Kenneth R. Meehan, Laleh Talebian,

Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets by Maria Nikolova, Jean-Daniel Lelievre, Matthieu.

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before.

Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia by Jochen Greiner, Yoko Ono, Susanne.

Volume 138, Issue 3, Pages (March 2010)

Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells by Martin R. Müller,

Fig. 1 pDCs infiltrate the skin of SSc patients and spontaneously secrete IFN-α and CXCL4. pDCs infiltrate the skin of SSc patients and spontaneously secrete.

Recovery of Varicella-Zoster Virus–Specific T Cell Immunity after T Cell–Depleted Allogeneic Transplantation Requires Symptomatic Virus Reactivation

Suppression of natural killer cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes J. Clausen, M. Enk, B. Vergeiner,

Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell–engrafted NOD/SCID/IL-2Rγcnull mice Simone Thomas,

Volume 25, Issue 8, Pages (August 2017)

HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,

Volume 33, Issue 1, Pages (July 2010)

FGF-2 signaling mediates expansion of HSPCs

Volume 127, Issue 3, Pages (September 2004)

Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma Mark Korthals, Nina Sehnke, Ralf Kronenwett,

Volume 39, Issue 4, Pages (October 2003)

A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2−

Volume 13, Issue 2, Pages (February 2006)

Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

TriKE–treated NK cells overcome MDSC-induced immune suppression.

Volume 24, Issue 6, Pages (June 2016)

Donor and recipient BAL T cells are phenotypically and functionally memory T cells. Donor and recipient BAL T cells are phenotypically and functionally.

Figure 1. MBP-specific IFN-γ+ but not IL-17+ frequencies are significantly different between patients with MS and HCs MBP-specific IFN-γ+ but not IL-17+

IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells by Ana Camelo, Guglielmo Rosignoli, Yoichiro.

Volume 21, Issue 4, Pages (April 2013)

Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma by Bethany Mundy-Bosse, Nathan Denlinger,

Cytotoxic activity of CD8+ T-cells stimulated with SSX2-derived p

Patient Tregs express normal levels of suppression.

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma by Alex F. Herrera, Alison.

Perturbations of natural killer cell regulatory functions in respiratory allergic diseases Francesca Scordamaglia, MD, Mirna Balsamo, PhD, Antonio Scordamaglia,

IL-9–expressing TH cells are highly enriched in CCR4+/CCR8+ effector memory TH cells. IL-9–expressing THcells are highly enriched in CCR4+/CCR8+effector.

CD123 CAR T cells for the treatment of myelodysplastic syndrome

Presentation transcript:

Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma by Carmen Choi, Mathias Witzens, Marianna Bucur, Markus Feuerer, Nora Sommerfeldt, Andreas Trojan, Anthony Ho, Volker Schirrmacher, Hartmut Goldschmidt, and Philipp Beckhove Blood Volume 105(5):2132-2134 March 1, 2005 ©2005 by American Society of Hematology

Frequencies and functional activity of MUC1-specific CD8 T cells in PB and BM of MM patients or healthy donors. Frequencies and functional activity of MUC1-specific CD8 T cells in PB and BM of MM patients or healthy donors. (A) One representative dot plot from a patient's PB showing tetramer binding cells among PI- mononuclear cells (2.5% tetramer binding cells among CD8+ T cells). (B) Frequencies of MUC1-specific CD8 T cells indicated as percent of total CD8 T cells from each individual patient (P; n = 50) and healthy donor (HD; n = 14) analyzed. The solid line indicates the maximum frequency measured in the group of healthy donors. The dotted line indicates maximum frequency of CD8 T cells binding HIV tetramers (n = 7). Significant differences between myeloma samples and corresponding samples from healthy donors are depicted for PB (†, P < .02) and BM (*, P < .05). Values from patients with elevated numbers of MUC1 specific CD8 T cells in either PB or BM are indicated by interrupted lines connecting corresponding values of PB and BM. As control, frequencies of the patient's CD8 T cells binding irrelevant tetramers containing HIV-derived peptide SLYNTVATL are shown (HIV). (C) Frequencies of IFN-γ secreting MUC1 peptide–reactive memory T cells in PB (▴; n = 10) and BM (⬡; n = 19) of altogether 21 myeloma patients (P) and of BM samples of 5 healthy donors (HD) (▵). Numbers of MUC1-reactive cells were calculated as difference between mean spot numbers in test wells and control wells and indicated as numbers of 106 purified T cells. †, overall significant difference between BM samples from myeloma patients and healthy donors (P < .05). *, overall significant difference between PB and BM of myeloma patients (P < .01). Values from patients with elevated numbers of MUC1-reactive T cells in either PB or BM are indicated by dotted lines connecting corresponding values of PB and BM. §, overall significant difference between PB and BM in paired samples from patients containing MUC1-reactive memory T cells (P < .02). (D) Percent of MUC1-specific lysis quantifies the significant difference between specific lysis of LLLLTVLTV-loaded T2 cells and lysis of T2 cells loaded with control peptide HLVEALYLV measured at an effector-target ratio of 25:1. No MUC1-specific cytotoxicity was observed in PB T cells at different effector-target ratios (6:1 vs 50:1). *, overall significant difference between cytotoxicity of BM T cells compared to PB T cells (P < .03). (E) Percent of perforin content of CD45RA- (⬡) and CD45RA+ CD8 T cells (○) from PB and BM samples of 3 myeloma patients after 7 days of coculture with autologous DCs pulsed with MUC1-derived peptide LLLLTVLTV. *, significant difference between perforin content of BM T cells compared to PB T cells (P = .04). Carmen Choi et al. Blood 2005;105:2132-2134 ©2005 by American Society of Hematology